Myeloproliferative disorder therapy: assessment and management of adverse events--a cardiologist's perspective.
Hematol Oncol
; 27 Suppl 1: 8-10, 2009 Jun.
Article
em En
| MEDLINE
| ID: mdl-19468985
ABSTRACT
Although some cardiac effects, such as palpitations and tachycardia, occur commonly in healthy people, they have also been shown to be associated with agents used to treat the myeloproliferative disorders. Various strategies exist to prevent and manage cardiac effects and minimise their impact on treatment compliance and persistence. These include pre-therapy cardiac assessment, pharmacological intervention and referral to a cardiologist. Ultimately, treating physicians must use their discretion when deciding which management strategy to use and which cardiac side effects require referral to a cardiologist, but the value of continuous dialogue between specialists should not be ignored.
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
Bases de dados:
MEDLINE
Assunto principal:
Cardiologia
/
Transtornos Mieloproliferativos
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Hematol Oncol
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Irlanda